Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients ...
The antibody drug conjugate didn’t help patients live longer in a confirmatory trial, prompting a review of its conditional ...
The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for ...
Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...
On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) announced plans to voluntarily withdraw the U.S. accelerated approval for ...
Gilead in 2021 won the FDA accelerated nod for Trodelvy in metastatic urothelial cancer, but continued approval was contingent on the outcome of a confirmatory study. The company in late May said that ...
Medpage Today on MSN1d
Drugmaker Pulls Trodelvy's Bladder Cancer ApprovalSacituzumab govitecan's (Trodelvy) accelerated approval in urothelial cancer will be voluntarily withdrawn, Gilead Sciences ...
Cheniere Energy moved one step closer to producing first liquefied natural gas from a Corpus Christi, Texas, expansion ...
The US pharma hopes that the drug will be used in those patients ... have been withdrawn in bladder cancer as a result. Gilead said Trodelvy’s safety profile in the TROPHY study is consistent ...
Gilead Sciences has bulked up its early-stage R&D portfolio with an agreement to buy XinThera, adding drugs targeting PARP for oncology and MK2 for inflammatory diseases. While the drug candidates ...
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback